Form 4: enGene Holdings Inc. Chief Medical Officer Acquires Stock Options

Raj Som Pruthi, Chief Medical Officer of enGene Holdings Inc., was granted stock options for 280,000 common shares on January 29, 2025.

Summary

• Raj Som Pruthi, the Chief Medical Officer of enGene Holdings Inc., was granted stock options to purchase 280,000 common shares.
• The options were granted on January 29, 2025, at an exercise price of $7.39 per share.
• These options vest monthly over a 48-month period, contingent upon Mr. Pruthi's continued employment with the company.
• The options expire on January 29, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of enGene Holdings Inc.'s stock price.
• If Mr. Pruthi leaves the company before the options fully vest, he may forfeit some or all of the options.

Future Outlook

The vesting of the stock options is contingent on the continued service of the Chief Medical Officer over the next 48 months.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in the biotech industry, similar to companies like Moderna, BioNTech, and Regeneron.
• The vesting schedule of 48 months is also typical, encouraging long-term commitment from the executive.
• The exercise price of $7.39 is specific to enGene's stock and market conditions at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Medical Officer to work towards increasing the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, executive compensation, insider trading, enGene Holdings Inc., ENGN, Chief Medical Officer, Raj Som Pruthi